-
Teva Announces Positive Results from a Phase III Study for QNAZE
Wednesday, February 9, 2011 - 9:12am | 92Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced results from a Phase III study of QNAZE HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis and seasonal allergic rhinitis. Results of the study evaluating patients with PAR showed...
-
US Stock Futures Signal Lower Start On Wall Street, Earnings In Focus
Wednesday, February 9, 2011 - 7:34am | 420US stock futures are lower this morning. Investors are awaiting comments from Federal Reserve Chairman Ben Bernanke. Futures for the Dow Jones Industrial Average dropped 22 points to 12,174.00, while those for the S&P 500 index declined 4.9 points to 1,316.80. Futures for the Nasdaq 100 index...
-
Fast Money Pops & Drops, February 8th (SVVS, TEVA, BDX, TSLA, MENT)
Tuesday, February 8, 2011 - 9:10pm | 256On CNBC's Fast Money Pops & Drops, Brian Kelly said that he likes SAVVIS, Inc. (NASDAQ: SVVS) because of its expanding margins. SAVVIS, Inc. (SVVS) gained 3.43% in the regular trading session, and it added 0.45% in the after hours. Karen Finerman was disappointed with Teva's (NASDAQ: TEVA)...
-
DURECT Announces Launch of First FDA Approved SABER Injectable Peptide Product
Tuesday, February 8, 2011 - 5:22pm | 124DURECT Corporation (Nasdaq: DRRX) today reported that its collaborator, CreoSalus, Inc., has launched commercial sales of its Food and Drug Administration (FDA) approved product known as SucroMate Equine, an injectable animal health drug utilizing DURECT's SABER™ technology to deliver the peptide...
-
Teva Pharmaceutical Industries Down 5.6% After Missing Estimates (TEVA)
Tuesday, February 8, 2011 - 4:44pm | 263Shares of Petach Tikva, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) are trading down 5.6% at $51.89 per share during the Tuesday afternoon trading session. The day's trading range for shares of Teva Pharmaceutical Industries has been between $51.18 and $52.40 per share. Analysts...
-
Future High Noon Showdown 02-08-2011
Tuesday, February 8, 2011 - 3:56pm | 900Cusick's Corner The market is continuing its grind higher in spite of the rate hike in China and the strike by workers in the Suez Canal. While it is hard to say that a top is in place, I am getting a sense that this grinding move higher is more like a high noon showdown between the bulls and the...
-
Teva Rocked After Earnings (TEVA)
Tuesday, February 8, 2011 - 1:49pm | 116Shares of Teva Pharmaceuticals (NASDAQ: TEVA) are falling on Tuesday after the company released its Q4 earnings results. The Israeli company reported adjusted net EPS of $1.25, which missed analysts' consensus estimates of $1.28. For fiscal 2011, TEVA sees earnings per share between $4.90 and $5....
-
Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on Regulatory Matters
Tuesday, February 8, 2011 - 12:48pm | 287Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (Nasdaq: CRXL) provide further information regarding Johnson & Johnson's proposed acquisition of Crucell. Reference is made to the joint press release of Johnson & Johnson and Crucell N.V. dated 8 December 2010 announcing the recommended...
-
Teva Provides 2011 Non-GAAP Financial Outlook
Tuesday, February 8, 2011 - 12:31pm | 98On its conference call today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) provided current outlook for its non-GAAP financial performance in 2011. For the full year, Teva expects net sales to be between $18.5 billion and $19.0 billion, with non-GAAP earnings per share (EPS) to be in the...
-
Morning Market Movers (RHB, OCLS, KND, NOVB)
Tuesday, February 8, 2011 - 11:00am | 155Rehabcare Group Inc (NYSE: RHB) jumped 46.25% to $37.25 at 10:00 am. Kindred Healthcare (NYSE: KND) agreed to purchase RHB for around $900 million in cash and stock. Oculus Innovative Sciences Inc (NASDAQ: OCLS) shares advanced 28.26% to $2.36. OCLS received a new FDA 510(k) clearance for its...
-
King Pharmaceuticals, Inc. Announces Intent to Voluntarily Delist From the NYSE
Tuesday, February 8, 2011 - 10:36am | 260King Pharmaceuticals, Inc. (NYSE: KG) announced today that it has submitted written notice to the New York Stock Exchange of its intention to voluntarily delist its common stock, no par value, from the NYSE. As previously announced on January 31, 2011, Pfizer Inc. (NYSE: PFE), through its wholly-...
-
Jefferies Comments On BMY Financials
Tuesday, February 8, 2011 - 10:26am | 118Jefferies is commenting on Bristol-Myers Squibb (NYSE: BMY) financials. “We expect positive newsflow on ipilimumab during Q1'11, specifically with regard to 1st-line melanoma data and the approval of a 2nd-line indication,” Jefferies writes. “Further visibility on apixaban in SPAF (Q2'11) and the...
-
Piper Jaffray Reiterates OW Rating, $60 PT On SLXP
Tuesday, February 8, 2011 - 9:24am | 134Yesterday, Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) announced the acquisition of worldwide rights (excluding Japan) to Progenics' Relistor (methylnaltrexone), Piper Jaffray reports. “A subcutaneous (SC) formulation is approved for the treatment of opioid-induced constipation (OIC) in patients...
-
Benzinga's Top Pre-Market NASDAQ Losers (PNNT, BBEP, TEVA, GLUU)
Tuesday, February 8, 2011 - 9:20am | 127PennantPark Investment Corporation (NASDAQ: PNNT) dropped 4.83% to $12.42 in the pre-market session. PNNT announced its plans to make a public offering of 7,500,000 shares of its common stock. BreitBurn Energy Partners LP (NASDAQ: BBEP) fell 4.42% to $21.20 in the pre-market session. BBEP...
-
Oculus Innovative Sciences Receives New FDA 510(k) Clearance for Microcyn-Based Dermatology HydroGel
Tuesday, February 8, 2011 - 9:14am | 116Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) announced today it had received a new FDA 510(k) clearance for its uniquely formulated Microcyn-based Epicyn HydroGel. Under the supervision of a healthcare professional, it is indicated to manage and relieve the burning, itching and pain experienced...